Benchmark set a $65.00 price objective on EXACT Sciences (NASDAQ:EXAS) in a research note issued to investors on Wednesday, January 17th. The firm currently has a buy rating on the medical research company’s stock.
Other analysts have also recently issued research reports about the company. Jefferies Group increased their target price on EXACT Sciences to $60.00 and gave the stock a buy rating in a report on Tuesday, October 31st. Bank of America set a $56.00 target price on EXACT Sciences and gave the stock a buy rating in a report on Thursday, October 19th. Robert W. Baird restated a buy rating and set a $49.00 target price on shares of EXACT Sciences in a report on Friday, October 6th. Canaccord Genuity reiterated a buy rating and issued a $60.00 price target (up previously from $45.00) on shares of EXACT Sciences in a report on Tuesday, October 3rd. Finally, Zacks Investment Research upgraded EXACT Sciences from a hold rating to a buy rating and set a $51.00 price target on the stock in a report on Tuesday, September 26th. Eight equities research analysts have rated the stock with a hold rating, nine have given a buy rating and one has assigned a strong buy rating to the stock. EXACT Sciences currently has a consensus rating of Buy and a consensus target price of $52.84.
EXACT Sciences (NASDAQ:EXAS) opened at $47.53 on Wednesday. The company has a debt-to-equity ratio of 0.01, a quick ratio of 9.98 and a current ratio of 10.34. EXACT Sciences has a 12 month low of $18.30 and a 12 month high of $63.60. The stock has a market capitalization of $5,690.00, a price-to-earnings ratio of -41.33 and a beta of 0.58.
In related news, insider Kevin T. Conroy sold 134,057 shares of EXACT Sciences stock in a transaction that occurred on Tuesday, November 21st. The stock was sold at an average price of $59.50, for a total value of $7,976,391.50. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, insider Kevin T. Conroy sold 110,439 shares of EXACT Sciences stock in a transaction that occurred on Tuesday, January 23rd. The shares were sold at an average price of $50.49, for a total value of $5,576,065.11. Following the completion of the sale, the insider now directly owns 940,491 shares in the company, valued at approximately $47,485,390.59. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 662,694 shares of company stock worth $35,934,015. 4.00% of the stock is currently owned by insiders.
Large investors have recently bought and sold shares of the business. C M Bidwell & Associates Ltd. acquired a new position in shares of EXACT Sciences during the 4th quarter worth approximately $117,000. Krilogy Financial LLC increased its position in shares of EXACT Sciences by 1,460.0% during the 2nd quarter. Krilogy Financial LLC now owns 3,900 shares of the medical research company’s stock worth $138,000 after purchasing an additional 3,650 shares during the last quarter. Northwestern Mutual Wealth Management Co. increased its position in shares of EXACT Sciences by 17.3% during the 2nd quarter. Northwestern Mutual Wealth Management Co. now owns 4,072 shares of the medical research company’s stock worth $144,000 after purchasing an additional 600 shares during the last quarter. Crow Point Partners LLC acquired a new position in shares of EXACT Sciences during the 4th quarter worth approximately $145,000. Finally, Oppenheimer Asset Management Inc. increased its position in shares of EXACT Sciences by 2,925.7% during the 3rd quarter. Oppenheimer Asset Management Inc. now owns 3,177 shares of the medical research company’s stock worth $150,000 after purchasing an additional 3,072 shares during the last quarter. 83.12% of the stock is currently owned by hedge funds and other institutional investors.
TRADEMARK VIOLATION NOTICE: This article was published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this article on another site, it was illegally copied and republished in violation of US & international copyright & trademark legislation. The original version of this article can be viewed at https://www.dispatchtribunal.com/2018/02/13/exact-sciences-exas-given-a-65-00-price-target-at-benchmark.html.
About EXACT Sciences
Exact Sciences Corporation is a molecular diagnostics company. The Company focuses on the early detection and prevention of some forms of cancer. It offers a non-invasive screening test called Cologuard for the early detection of colorectal cancer and pre-cancer. Its Cologuard test is a stool-based deoxyribonucleic acid (sDNA) screening test, which utilizes a multi-target approach to detect deoxyribonucleic acid (DNA) and hemoglobin biomarkers associated with colorectal cancer and pre-cancer.
Receive News & Ratings for EXACT Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for EXACT Sciences and related companies with MarketBeat.com's FREE daily email newsletter.